Elanco Animal Health Incorporated (ELAN) EBITDA
- 2026-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $172.00M.
- 2025-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $161.00M.
- 2024-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $166.00M.
- 2023-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization $173.00M.
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Reported | (m) | (m) | $172.00M | $1.37B | (m) | $51.00M | $13.00M | $586.00M | $97.00M | $381.00M | $30.00M |
| 2025-03-31 | Reported | (m) | (m) | $161.00M | $1.19B | (m) | $65.00M | -$4.00M | $509.00M | $94.00M | $341.00M | -$7.00M |
| 2024-03-31 | Reported | (m) | (m) | $166.00M | $1.21B | (m) | $24.00M | $2.00M | $515.00M | $87.00M | $337.00M | -$20.00M |
| 2023-03-31 | Reported | (m) | (m) | $173.00M | $1.26B | (m) | $24.00M | -$145.00M | $494.00M | $81.00M | $327.00M | $5.00M |
| 2022-03-31 | Reported | (m) | (m) | $176.00M | $1.23B | (m) | $19.00M | -$62.00M | $509.00M | $81.00M | $323.00M | $24.00M |
| 2021-03-31 | Reported | (m) | (m) | $202.00M | $1.24B | (m) | $18.00M | $22.00M | $566.00M | $89.00M | $349.00M | -$13.00M |
| 2020-03-31 | Reported | (m) | (m) | $82.00M | $658.00M | (m) | $13.00M | $4.00M | $333.00M | $67.00M | $182.00M | -$19.00M |
| 2019-03-31 | Reported | (m) | (m) | $75.20M | $731.10M | (m) | $28.00M | $8.10M | $343.80M | $64.10M | $181.10M | $13.30M |
| 2018-03-31 | Reported | (m) | (m) | $74.30M | $736.20M | (m) | $32.70M | $47.00M | $360.00M | $65.20M | $180.00M | $4.80M |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | (m) | $680.00M | $4.71B | (m) | $276.00M | $560.00M | $2.12B | $368.00M | $1.43B | $8.00M |
| 2024-12-31 | Reported | (m) | (m) | $662.00M | $4.44B | (m) | $147.00M | $541.00M | $2.00B | $344.00M | $1.31B | $150.00M |
| 2023-12-31 | Reported | (m) | (m) | $694.00M | $4.42B | (m) | $140.00M | $271.00M | $1.93B | $327.00M | $1.28B | $36.00M |
| 2022-12-31 | Reported | (m) | (m) | $682.00M | $4.41B | (m) | $171.00M | $452.00M | $1.91B | $321.00M | $1.26B | $6.00M |
| 2021-12-31 | Reported | (m) | (m) | $716.00M | $4.76B | (m) | $159.00M | $483.00M | $2.13B | $369.00M | $1.40B | -$88.00M |
| 2020-12-31 | Reported | (m) | (m) | $517.00M | $3.27B | (m) | $135.00M | -$41.00M | $1.67B | $329.00M | $997.00M | -$103.00M |
| 2019-12-31 | Reported | (m) | (m) | $314.00M | $3.07B | (m) | $140.00M | $224.00M | $1.47B | $270.00M | $760.00M | $10.00M |
| 2018-12-31 | Reported | (m) | (m) | $296.00M | $3.07B | (m) | $134.50M | $487.30M | $1.57B | $246.60M | $735.20M | $27.60M |
| 2017-12-31 | Reported | (m) | (m) | $318.40M | $2.89B | (m) | $98.60M | $173.80M | $1.49B | $251.70M | $779.80M | $78.10M |
| 2016-12-31 | Reported | (m) | (m) | $254.40M | $2.91B | (m) | $110.30M | $155.90M | $1.41B | $265.80M | $784.80M | $25.50M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |